S&P 500   5,056.06 (-0.11%)
DOW   37,813.03 (+0.21%)
QQQ   430.58 (-0.11%)
AAPL   168.96 (-2.16%)
MSFT   415.18 (+0.37%)
META   500.17 (-0.01%)
GOOGL   154.61 (-0.16%)
AMZN   183.25 (-0.20%)
TSLA   155.92 (-3.44%)
NVDA   873.68 (+1.59%)
AMD   162.85 (+1.58%)
NIO   3.85 (-1.03%)
BABA   69.93 (-0.98%)
T   15.98 (-1.60%)
F   12.13 (-0.82%)
MU   121.20 (-0.14%)
GE   155.63 (+1.26%)
CGC   6.84 (-2.01%)
DIS   113.75 (+0.71%)
AMC   2.81 (+13.77%)
PFE   25.74 (-0.66%)
PYPL   63.53 (+0.03%)
XOM   118.47 (-1.01%)
S&P 500   5,056.06 (-0.11%)
DOW   37,813.03 (+0.21%)
QQQ   430.58 (-0.11%)
AAPL   168.96 (-2.16%)
MSFT   415.18 (+0.37%)
META   500.17 (-0.01%)
GOOGL   154.61 (-0.16%)
AMZN   183.25 (-0.20%)
TSLA   155.92 (-3.44%)
NVDA   873.68 (+1.59%)
AMD   162.85 (+1.58%)
NIO   3.85 (-1.03%)
BABA   69.93 (-0.98%)
T   15.98 (-1.60%)
F   12.13 (-0.82%)
MU   121.20 (-0.14%)
GE   155.63 (+1.26%)
CGC   6.84 (-2.01%)
DIS   113.75 (+0.71%)
AMC   2.81 (+13.77%)
PFE   25.74 (-0.66%)
PYPL   63.53 (+0.03%)
XOM   118.47 (-1.01%)
S&P 500   5,056.06 (-0.11%)
DOW   37,813.03 (+0.21%)
QQQ   430.58 (-0.11%)
AAPL   168.96 (-2.16%)
MSFT   415.18 (+0.37%)
META   500.17 (-0.01%)
GOOGL   154.61 (-0.16%)
AMZN   183.25 (-0.20%)
TSLA   155.92 (-3.44%)
NVDA   873.68 (+1.59%)
AMD   162.85 (+1.58%)
NIO   3.85 (-1.03%)
BABA   69.93 (-0.98%)
T   15.98 (-1.60%)
F   12.13 (-0.82%)
MU   121.20 (-0.14%)
GE   155.63 (+1.26%)
CGC   6.84 (-2.01%)
DIS   113.75 (+0.71%)
AMC   2.81 (+13.77%)
PFE   25.74 (-0.66%)
PYPL   63.53 (+0.03%)
XOM   118.47 (-1.01%)
S&P 500   5,056.06 (-0.11%)
DOW   37,813.03 (+0.21%)
QQQ   430.58 (-0.11%)
AAPL   168.96 (-2.16%)
MSFT   415.18 (+0.37%)
META   500.17 (-0.01%)
GOOGL   154.61 (-0.16%)
AMZN   183.25 (-0.20%)
TSLA   155.92 (-3.44%)
NVDA   873.68 (+1.59%)
AMD   162.85 (+1.58%)
NIO   3.85 (-1.03%)
BABA   69.93 (-0.98%)
T   15.98 (-1.60%)
F   12.13 (-0.82%)
MU   121.20 (-0.14%)
GE   155.63 (+1.26%)
CGC   6.84 (-2.01%)
DIS   113.75 (+0.71%)
AMC   2.81 (+13.77%)
PFE   25.74 (-0.66%)
PYPL   63.53 (+0.03%)
XOM   118.47 (-1.01%)
Free Trial

Greenwich LifeSciences (GLSI) Stock Forecast & Price Target

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)
Free GLSI Stock Alerts
$14.49
+0.23 (+1.61%)
(As of 02:22 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media

Greenwich LifeSciences Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 1 Analyst Ratings

Analysts' Consensus Price Target

$36.00
148.45% Upside
High Forecast$36.00
Average Forecast$36.00
Low Forecast$36.00
TypeCurrent Forecast
4/17/23 to 4/16/24		1 Month Ago
3/18/23 to 3/17/24		3 Months Ago
1/17/23 to 1/17/24		1 Year Ago
4/17/22 to 4/17/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$36.00$36.00$38.00$38.00
Predicted Upside148.45% Upside202.78% Upside195.26% Upside195.26% Upside
Get Greenwich LifeSciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.

GLSI Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GLSI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Greenwich LifeSciences Stock vs. The Competition

TypeGreenwich LifeSciencesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside152.45% Upside882.30% Upside11.22% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/28/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$36.00+202.78%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:48 PM ET.

GLSI Price Target - Frequently Asked Questions

What is Greenwich LifeSciences's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Greenwich LifeSciences stock is Buy based on the current 1 buy rating for GLSI. The average twelve-month price prediction for Greenwich LifeSciences is $36.00 with a high price target of $36.00 and a low price target of $36.00. Learn more on GLSI's analyst rating history.

Do Wall Street analysts like Greenwich LifeSciences more than its competitors?

Analysts like Greenwich LifeSciences more than other Medical companies. The consensus rating for Greenwich LifeSciences is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how GLSI compares to other companies.

Does Greenwich LifeSciences's stock price have much upside?

According to analysts, Greenwich LifeSciences's stock has a predicted upside of 202.78% based on their 12-month stock forecasts.

What analysts cover Greenwich LifeSciences?

Greenwich LifeSciences has been rated by HC Wainwright in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:GLSI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The “Perfect Storm” for Gold
Gold Safe Exchange
Top 5 AI Stocks to Buy for 2024
Market Moving Trends